Chemotherapy for mycosis fungoides and the Sézary syndrome.
Although conventional cytotoxic chemotherapy agents used alone or in combination have demonstrated activity in MF/SS, there are no studies that clearly demonstrate improvement in survival of treated patients. Newer compounds worthy of further clinical investigation in these patients include temazolamide, an alkylating agent with activity in brain neoplasms, the taxanes, and topoisomerase inhibitors, including topotecan and CPT-11. In addition, the combination of cytotoxic chemotherapies with biologic modalities, such as targeted toxins and immunomodulatory agents, has yet to be explored.
Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, USA.
S T
ST
Rosen
F M
FM
Foss
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004583:Electrons; D006801:Humans; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000532:radiotherapy; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000532:radiotherapy
D000970:Antineoplastic Agents